Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia.

Federica Pilotto, Deepika M Chellapandi, Hélène Puccio

Trends in molecular medicine 2024 Feb

filter terms:

Friedreich ataxia (FA) is an inherited autosomal recessive neurodegenerative disease (NDD) characterized primarily by progressive sensory and spinocerebellar ataxia associated with hypertrophic cardiomyopathy. FA is due to an intronic GAA repeat expansion within the frataxin gene (FXN) leading to reduced levels of frataxin (FXN) which causes mitochondrial dysfunction, production of reactive oxygen species (ROS), and altered iron metabolism. To date there is no resolutive cure for FA; however, the FDA has recently approved omaveloxolone - a potent activator of nuclear factor erythroid 2-related factor 2 (NRF2) - as the first treatment for FA. We discuss herein the urgency to find a resolutive cure for NDDs that will most probably be achieved via combinatorial therapy targeting multiple disease pathways, and how omavaloxolone serves as an example for future treatments. Copyright © 2023 Elsevier Ltd. All rights reserved.

Citation

Federica Pilotto, Deepika M Chellapandi, Hélène Puccio. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia. Trends in molecular medicine. 2024 Feb;30(2):117-125